Fundamenta Therapeutics, Ltd. Report issue

For profit Phase 1 Phase 2
Founded: Düsseldorf Germany (2012)

Organization Overview

First Clinical Trial
2020
NCT05127135
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Fundamenta Therapeutics, Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 6